Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Editas Medicine (EDIT) has shared an update.
Akshay Vaishnaw will resign from the Board of Directors of Editas Medicine, Inc. on June 30, 2024. His departure is not due to any disputes over the company’s operations, policies, or practices.
For a thorough assessment of EDIT stock, go to TipRanks’ Stock Analysis page.